Incyte stock

INCY · NASDAQ · USD

Compare Incyte
$119.09Change from previous close: −0.98%Absolute change: −$1.18

Close · November 17, 2026

Price history

+15.54% over the period

1 year: from $104.17 (November 17, 2025) to $120.36 (November 17, 2026), +15.54%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$120.36
October 30, 2026$120.39
September 30, 2026$121.35
August 31, 2026$123.22
July 31, 2026$119.52
June 30, 2026$113.36
May 29, 2026$96.74
April 30, 2026$95.27
March 31, 2026$94.12
February 27, 2026$101.27
January 30, 2026$100.07
December 31, 2025$98.77
November 28, 2025$104.46
November 17, 2025$104.17

At a glance

  • The company

    Discovers, develops and commercializes biopharmaceutical therapeutics in the United States, Europe, Canada and Japan

  • Latest results

    Quarter to September 30, 2026 · EPS -$3.60 (estimate -$3.53)

TickerLandia's take on Incyte

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$89.25
52-wk high$132.60

−10.19% from the 52-week high

Analysts · 28 analysts

Average target$132.25+11.05% vs. price

Buy 13 · Hold 14 · Sell 1 · Buy

TickerLandia Fingerprint: Incyte

Compared with similar companies: very high financial strength.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Incyte is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Incyte's P/E today is 18.8, below the median of its last 7 fiscal years (42.6; between 15.4 and 185.7 from 2016 to 2025). Incyte's P/E (trailing 12 months): 61.0, +86% against the median of a group of 6 similar companies (32.7).

P/E compared with its history

Compared with 6 similar companies

Incyte's metrics compared with similar companies
MetricIncytePosition in the groupBand
P/E (trailing 12 months)61.0High
Forward P/E13.9Middle
Operating margin32.2%High
ROE7.8%Middle
Debt/equity0.01Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Incyte. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.56B

Latest quarter · Q3 2026

Net income

-$784.8M

Latest quarter · Q3 2026

Quarterly net margin

-50.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$24.36B
P/E
61.0
EPS
$1.96
Volume
858.15K
Daily trading
€195.71M
Dividend yield
0.00%

How Incyte is changing

All results
  • Revenue grew 14.0% a year on average over the last 5 years

  • Operating margin rose from 17.1% to 29.5%

  • Profits turn into cash: free cash flow equal to 108% of net income

Returns

Incyte returns

$1,000 invested in Incyte 5 years ago, on November 17, 2021, would be worth $1,851 today: +85.11% in total, +13.11% per year. This is the price return only: dividends are excluded.

PeriodIncyteS&P 500$1,000 becomes
1 month+6.28%−3.17%$1,063
6 months+24.95%+0.11%$1,250
Year to date+21.86%+8.34%$1,219
1 year+15.54%+11.15%$1,155
3 years+121.78%+64.30%$2,218
5 years+85.11%+58.18%$1,851
10 years+14.03%+239.10%$1,140

Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Incyte: technical analysis

Incyte is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 22.0% below its all-time closing high ($152.66, March 15, 2017).

Trend
Upward
RSI (14 sessions)
50
Between 30 and 70
vs 200-session average
+9.16%

Support and resistance

Price areas where Incyte has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$129.84+9.03%3 touches, last on September 18, 2026
  2. Resistance$119.51+0.36%3 touches, last on September 15, 2026
  3. Last price$119.09
  4. Support$115.38−3.11%2 touches, last on November 6, 2026
  5. Support$111.05−6.75%4 touches, last on October 29, 2026
  6. Support$108.36−9.01%4 touches, last on October 13, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.48
Volatility (60 sessions, annualised)
29.0%
Largest fall in the last year
−18.33%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Incyte: seasonality

Average monthly price change over 33 years

+8.4%Jan−0.1%Feb−4.0%Mar−1.0%Apr+6.0%May+2.9%Jun+1.7%Jul+2.0%Aug−1.3%Sep+2.0%Oct+6.1%Nov+9.1%Dec

Over the last 33 years, the strongest month for Incyte has been December: +9.13% on average, positive in 19 years out of 33. The weakest has been March: −3.98% on average, positive in 14 years out of 33. November, the current month, has been positive in 19 years out of 32 (+6.09% on average).

Show chart data
MonthAverageMedianPositive years
January+8.42%+7.37%21 of 33
February−0.15%−3.14%11 of 33
March−3.98%−1.89%14 of 33
April−1.04%−0.28%16 of 33
May+6.02%+2.04%20 of 33
June+2.87%+1.19%20 of 33
July+1.71%+0.71%18 of 33
August+1.95%+1.27%18 of 33
September−1.33%−5.38%13 of 33
October+2.01%+2.23%17 of 33
November+6.09%+1.78%19 of 32
December+9.13%+2.89%19 of 33

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Incyte and its competitors

JAKAFI, ICLUSIG, MONJUVI, NIKTIMVO, PEMAZYRE and ZYNYZ are the Incyte Corporation medicines most widely known, and the company discovers, develops and commercializes therapeutics. Its marketed products treat myelofibrosis, polycythemia vera, chronic myeloid leukemia, diffuse large B-cell lymphoma and Merkel cell carcinoma, while clinical-stage candidates target ovarian cancer, atopic dermatitis, hidradenitis suppurativa and vitiligo. Products are sold to specialty and retail pharmacies, hospital pharmacies and distributors in the United States, Europe, Canada and Japan.

Headquarters
Wilmington, United States
Employees
2,844
Founded
1991
Chief executive
William Meury
Incyte and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IncyteINCY$24.36B32.2%61.0+24.95%
Alnylam PharmaceuticalsALNY$22.11B19.5%8.34−45.47%
InsmedINSM$26.96B-41.7%—+11.65%
BioNTechBNTX$21.22B-55.4%—−5.24%
Roivant SciencesROIV$28.64B-3,226.3%—+32.16%
Ascendis PharmaASND$18.06B30.9%18.1+12.76%

Same industry or related industries, similar size. Compare Incyte with its competitors · Full profile